Cargando…

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis

BACKGROUND: Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8(+) T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iafolla, Marco A J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J, Siu, Lillian L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853183/ https://www.ncbi.nlm.nih.gov/pubmed/33554038 http://dx.doi.org/10.1093/jncics/pkaa115

Ejemplares similares

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020)

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
por: Clouthier, Derek L., et al.
Publicado: (2019)

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
por: Cindy Yang, S. Y., et al.
Publicado: (2021)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
por: Araujo, Daniel V, et al.
Publicado: (2021)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
por: Cunningham, Morven, et al.
Publicado: (2021)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
por: Janse van Rensburg, Helena J., et al.
Publicado: (2023)

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
por: Day, Daphne, et al.
Publicado: (2019)

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
por: Ala‐Leppilampi, Kari, et al.
Publicado: (2020)

Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor
por: Quevedo, Rene, et al.
Publicado: (2020)

Increasing operational and scientific efficiency in clinical trials
por: Kelly, Deirdre, et al.
Publicado: (2020)

A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT
por: Almousawi, F, et al.
Publicado: (2023)

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
por: Voon, Pei Jye, et al.
Publicado: (2022)

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
por: Genta, Sofia, et al.
Publicado: (2023)

Lung cancer in never smokers from the Princess Margaret Cancer Centre
por: Korpanty, Grzegorz J., et al.
Publicado: (2018)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
por: Lundy, Joanne, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria
por: Wintersperger, Bernd J, et al.
Publicado: (2022)

Additional germline findings from a tumor profiling program
por: Stjepanovic, Neda, et al.
Publicado: (2018)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
por: Pezo, Rossanna C., et al.
Publicado: (2017)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
por: O’Neil, Bert H., et al.
Publicado: (2017)

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
por: Diaz-Padilla, Ivan, et al.
Publicado: (2013)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
por: Richter, Suzanne, et al.
Publicado: (2013)

FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors
por: Ezzat, Shereen, et al.
Publicado: (2016)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
por: Razak, Albiruni RA, et al.
Publicado: (2020)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer
por: Aung, Kyaw L., et al.
Publicado: (2016)

Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report
por: Botta, Cirino, et al.
Publicado: (2021)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2021)

CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis
por: Dursi, L. Jonathan, et al.
Publicado: (2021)

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor‐specific HLA variants
por: Anzar, Irantzu, et al.
Publicado: (2022)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
por: Stockley, Tracy L., et al.
Publicado: (2016)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i1krfcea0qdq7j8af6ua9a77q8